China Journal of Oral and Maxillofacial Surgery ›› 2022, Vol. 20 ›› Issue (4): 313-319.doi: 10.19438/j.cjoms.2022.04.001

• Expert Consensus • Previous Articles     Next Articles

Chinese experts consensus on the use of oral propranolol for treatment of infantile hemangiomas(version 2022)

ZHENG Jia-wei1, WANG Xu-kai2, QIN Zhong-ping3, FAN Xin-dong4, LI Kai5, YANG Yao-wu6, HUO Ran7, LIU Shao-hua8, ZHAO Ji-hong9, WANG Xiao-yong10, ZHOU De-kai11, LIU Xue-jian12   

  1. 1. Department of Oral and Maxillofacial Surgery, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine. Shanghai 200011;
    2. Department of Oral and Maxillofacial Surgery, School of Stomatology, China Medical University; Liaoning Institute of Dental Research. Shenyang 110001, Liaoning Province;
    3. Special Department of Hemangioma, Tumor Hospital of Linyi City. Linyi 276001, Shandong Province;
    4. Department of Intervention Therapy, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine. Shanghai 200011;
    5. Department of Pediatric Surgery, Children's Hospital of Fudan University. Shanghai 201102;
    6. Department of Head and Neck Tumor Surgery, School of Stomatology, Air Force Military Medical University. Xi'an 710032, Shaanxi Province;
    7. Department of Aesthetic Plastic and Burn Surgery, Shandong Provincial Hospital, Shandong First Medical University. Jinan 250021,Shandong Province;
    8. Department of Oral and Maxillofacial Surgery, Qilu Hospital, Shandong University. Jinan 250012,Shandong Province;
    9. Department of Oral Surgery, School of Stomatology, Wuhan University. Wuhan 430079, Hubei Province;
    10. Department of Infantile Hemangioma, Shanghai Cao'an Hospital. Shanghai 201804;
    11. Department of Infantile Hemangioma, Gastrointestinal and Neonatal Surgery, Children's Hospital of Chongqing Medical University. Chongqing 400014;
    12. Department of Thyroid Gland, Mammary Gland and Hemangiomas, Shandong Provincial Third Hospital. Jinan 250031, Shandong Province,China
  • Received:2022-06-01 Revised:2022-06-15 Online:2022-07-20 Published:2022-08-02

Abstract: Since 2008, propranolol has become the first-line treatment for infantile hemangiomas. Many researches have been reported on its treatment mechanism both at home and abroad, and several expert consensus or clinical practice guidelines have been formulated and published. In recent years, with the continuous accumulation of clinical experience, increasing number of basic research works, and deepening understanding of the pathogenesis of hemangioma and the mechanism of action of propranolol, it is necessary to update the expert consensus to be more consistent with clinical practice, in order to guide medication and management, provide scientific norms for the clinical use of propranolol in the treatment of infantile hemangiomas. This updated version mainly simplified the process of clinical examination, medication, and monitoring, making it more convenient and operable.

Key words: Propranolol, Infantile hemangioma, Experts consensus

CLC Number: